Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status approved
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 69784-610; 49452-1911; 76055-0025; 80725-610; 50683-0384; 76388-635; 71052-212
UNII 18D0SL7309
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.001--
Dyspnoea02.11.05.003; 22.02.01.0040.000884%
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.000616%
Feeling abnormal08.01.09.014--Not Available
Gastrooesophageal reflux disease07.02.02.0030.000168%
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemolytic anaemia01.06.03.002--Not Available
Hallucination19.10.04.003--
Hepatic failure09.01.03.0020.000168%
Hepatitis09.01.07.0040.000112%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.009--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.000112%
Hyperhidrosis08.01.03.028; 23.02.03.0040.000224%
Hyperpyrexia08.05.02.0020.000112%Not Available
Hypersensitivity10.01.03.0030.000168%
Hyperuricaemia14.09.01.003--
Hyponatraemia14.05.04.0020.000168%
Hypotension24.06.03.0020.000672%
Hypoxia22.02.02.0030.000168%
Infection11.01.08.002--Not Available
Infertility21.03.02.001--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukaemia01.10.03.001; 16.01.03.001--
Leukopenia01.02.02.0010.000392%Not Available
Lymphadenopathy01.09.01.0020.000112%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene